tRNA-Derived Fragments as Novel Predictive Biomarkers for Trastuzumab-Resistant Breast Cancer

Chunxiao Sun1,2, Fan Yang1,2, Yanhong Zhang1,2

  • 1Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Abstract

Insights

Two tRNA-derived fragments, tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN, are linked to trastuzumab resistance in HER-2 positive breast cancer. Higher levels of these fragments indicate poorer response to trastuzumab therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Trastuzumab resistance is a significant obstacle in treating HER-2 positive breast cancer.
  • The mechanisms underlying trastuzumab resistance are not fully understood.
  • tRNA-derived small non-coding RNAs (sncRNAs) are emerging as key players in cancer progression.

Purpose of the Study:

  • To investigate the role of tRNA-derived fragments (tRFs) in trastuzumab resistance in HER-2 positive breast cancer.
  • To identify potential biomarkers for predicting response to trastuzumab therapy.

Main Methods:

  • High-throughput sequencing to detect tRF expression in breast cancer cell lines.
  • Quantitative reverse transcription PCR (qRT-PCR) to validate tRF levels in patient serum.
  • Receiver operating characteristic (ROC) curve analysis to assess diagnostic power.
  • Cox-regression analysis for progression-free survival (PFS).

Main Results:

  • tRFs were differentially expressed in trastuzumab-sensitive and -resistant cell lines.
  • tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN were significantly upregulated in trastuzumab-resistant patients.
  • ROC analysis confirmed the association of these tRFs with trastuzumab resistance.
  • Elevated levels of tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN correlated with shorter PFS in metastatic HER-2 positive breast cancer patients.

Conclusions:

  • tRF-30-JZOYJE22RR33 and tRF-27-ZDXPHO53KSN are implicated in trastuzumab resistance.
  • Patients with high expression of these tRFs may benefit less from trastuzumab treatment.
  • These tRFs show potential as biomarkers and therapeutic targets for trastuzumab-resistant breast cancer.

Related Concept Videos

tRNA Activation02:26

tRNA Activation

Aminoacyl-tRNA synthetases are present in both eukaryotes and bacteria. Though eukaryotes have 20 different aminoacyl-tRNA synthetases to couple to 20 amino acids, many bacteria do not have genes for all of these aminoacyl-tRNA synthetases. Despite this, they still use all 20 amino acids to synthesize their proteins. For instance, some bacteria do not have the gene encoding the enzyme that couples glutamine with its partner tRNA. In these organisms, one enzyme adds glutamic acid to all of the...
23.0K
tRNA Activation02:26

tRNA Activation

8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Habitat Fragmentation02:31

Habitat Fragmentation

Habitat fragmentation describes the division of a more extensive, continuous habitat into smaller, discontinuous areas. Human activities such as land conversion, as well as slower geological processes leading to changes in the physical environment, are the two leading causes of habitat fragmentation. The fragmentation process typically follows the same steps: perforation, dissection, fragmentation, shrinkage, and attrition.
21.4K
Predicting Molecular Geometry02:27

Predicting Molecular Geometry

VSEPR Theory for Determination of Electron Pair Geometries
46.0K